It is premature to consider kisspeptin-54 as a therapeutic for HA; however, one potential advantage of administering kisspeptin-54 over GnRH would be its suitability for constant pump administration, which is increasingly used to deliver insulin therapy to certain patients with diabetes (42). The gene discussed is KISS1; the disease is diabetes mellitus.